Self-contained presentation
A compact powder-and-solvent format developed for administration without a separate glass of water.
Norwegian pharmaceutical company
A differentiated cardiovascular asset. Built for the moment that matters.
Asamedic is developing and commercialising Coxor®, its lead pharmaceutical asset: a 300 mg acetylsalicylic acid formulation with an established European regulatory foundation.
Coxor® 300 mgLead pharmaceutical asset for emergency cardiovascular care.RegulatoryEuropean approval and Norwegian launch
EvidencePeer-reviewed clinical publication
ProtectionPatent protection in multiple jurisdictions
GrowthAspen and market partners across international territories
Why Asamedic
Turning a clear emergency-care need into a scalable pharmaceutical opportunity.
Asamedic focuses on the prehospital emergency-care pathway, where practical barriers can affect how quickly established treatment options are made available.
Coxor® provides the company with a differentiated, regulated asset around which to build partnerships, market access and responsible commercialisation.
Discover AsamedicThe asset
Coxor® is designed around practical administration and readiness.
A powder and solvent for oral solution, developed for an emergency-care setting.
See the product storyEvidence-led development
Supported by formulation development, pharmacokinetic work and a peer-reviewed publication.
Protected asset
Patent protection and regulatory experience create meaningful barriers to entry.
Built for international scale
A partner-led model for bringing Coxor® to more markets.
Asamedic combines pharmaceutical ownership, regulatory execution and manufacturing readiness with local partners who understand their markets.
2021European DCP approval completed
2023Norwegian commercial launch
NextPartner-led international expansion
Leadership & governance
Experienced leadership for the next phase.
Asamedic is supported by a team and board combining pharmaceutical, regulatory, commercial, financial and cardiovascular expertise.
Meet the teamLet’s talk
Interested in Coxor® or a market partnership?
We are open to conversations with pharmaceutical companies, licensing partners and stakeholders who share our ambition to improve early cardiovascular care.
Start a conversation